Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Grace Therapeutics, Inc.GRCE · Entity 7266 | VP Program Management | August 28, 2026 | September 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Grace Therapeutics, Inc.
Report date August 28, 2026 · Filed September 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.12 · Expires 2036-08-27 | Direct | 35,760 |
Reported balance
After 2026-08-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-28 · Grant · Acquired 35,760 · Balance 35,760 F1: These options vest quarterly in substantially equal installments over a three-year period, subject to the Reporting Person's continuous service as of each vesting date, The first 1/12 tranche shall vest immediately upon the grant date with the remaining 11/12 vesting equally over the following 11 quarters starting on the three-month anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: These options vest quarterly in substantially equal installments over a three-year period, subject to the Reporting Person's continuous service as of each vesting date, The first 1/12 tranche shall vest immediately upon the grant date with the remaining 11/12 vesting equally over the following 11 quarters starting on the three-month anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 28, 2026 Filed Sep 1, 2026 20:05 UTC | Grace Therapeutics, Inc. GRCE · Entity 7266 | GrantStock Option (Right to Buy) · Derivative | 35,760 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001140361-26-035318 · form4.xml · derivative · entry 1 Kumar Amresh · CIK 0001978220 · VP Program Management 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,760 Underlying: Common Stock · 35,760 shares Expires 2036-08-27 F1 · derivative.exercise_date: These options vest quarterly in substantially equal installments over a three-year period, subject to the Reporting Person's continuous service as of each vesting date, The first 1/12 tranche shall vest immediately upon the grant date with the remaining 11/12 vesting equally over the following 11 quarters starting on the three-month anniversary of the grant date. Read SEC document |
| April 14, 2025 Filed Apr 17, 2025 00:58 UTC | Grace Therapeutics, Inc. GRCE · Entity 7266 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.08 | $0.00 |
DisclosureSEC source: 0001140361-25-014266 · form4.xml · derivative · entry 1 Kumar Amresh · CIK 0001978220 · VP Program Management 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-04-14 F1 · derivative.exercise_date: This option vests quarterly in substantially equal installments over a 3-year period, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| May 06, 2024 Filed May 8, 2024 23:19 UTC | Grace Therapeutics, Inc. ACST · Entity 7266 | GrantStock Options (Right to Buy) · Derivative | 19,740 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0000950170-24-056084 · ownership.xml · derivative · entry 1 Kumar Amresh · CIK 0001978220 · VP Clinical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,740 Underlying: Class A Common Shares · 19,740 shares Expires 2034-05-06 F1 · derivative.exercise_date: Stock options granted on 05/06/2024 under the Acasti Pharma Stock Option Plan, which vest quarterly in equal installments over a 36-month period. Read SEC document |
| May 06, 2024 Filed May 10, 2024 20:07 UTC Amendment | Grace Therapeutics, Inc. ACST · Entity 7266 | GrantStock Options (Right to Buy) · Derivative | 19,740 | $0.00 Strike: $2.96 | $0.00 |
DisclosureSEC source: 0000950170-24-057811 · ownership.xml · derivative · entry 1 Kumar Amresh · CIK 0001978220 · VP Program Management 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,740 Underlying: Class A Common Shares · 19,740 shares Expires 2034-05-06 F1 · date: This amendment to Form 4 is being filed to amend the signature block in the original Form 4, filed on May 8, 2024, to reflect the correct signatory. F2 · derivative.exercise_date: Stock options granted on 05/06/2024 under the Acasti Pharma Stock Option Plan, which vest quarterly in equal installments over a 36-month period. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 20:28 UTC | Grace Therapeutics, Inc. ACST · Entity 7266 | GrantStock Options (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001062993-23-014995 · form4.xml · derivative · entry 1 Kumar Amresh · CIK 0001978220 · VP Program Management 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,000 Underlying: Class A Common Shares · 42,000 shares Expires 2033-07-14 F1 · derivative.exercise_date: Stock options granted on 07/14/2023 under the Acasti Pharma Stock Option Plan, which vest and become exercisable in equal quarterly installments over a period of 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.